The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial

Published:2023-03 Issue:3 Volume:10 Page:e178-e190
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Xuan Li,Dai Min,Jiang Erlie,Wang Yu,Huang Fen,Fan Zhiping,Xu Na,Nie Danian,Liang Xinquan,Chen Hong,Ye Jieyu,Shi Pengcheng,Liu Hui,Jin Hua,Lin Ren,Yan Chenhua,Zhang Yu,Sun Jing,Han Mingzhe,Liu Qifa

Funder

Special Project for Research and Development in Key areas of Guangdong Province

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Southern Medical University

National Key Research and Development Program of China

Publisher

Elsevier BV

Subject

Hematology

Reference33 articles.

1. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation;Lindsley;N Engl J Med,2017